PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34682854-5	2021	Ivabradine, a heartrate-reducing agent, an inhibitor of HCN channels, may be one of such options.	Ivabradine	0-10	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	56-59	
25911606-0	2015	hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.	Ivabradine	79-89	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	39-42	
25911606-1	2015	BACKGROUND: Ivabradine is a specific bradycardic agent used in coronary artery disease and heart failure, lowering heart rate through inhibition of sinoatrial nodal HCN-channels.	Ivabradine	12-22	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	165-168	
23308150-3	2013	Different studies suggest that the binding site of ivabradine is located in the inner vestibule of HCN channels, but the molecular details of ivabradine binding are unknown.	Ivabradine	51-61	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	99-102	
23308150-4	2013	We thus sought to investigate by mutagenesis and in silico analysis which residues of the HCN4 channel, the HCN isoform expressed in the sinoatrial node, are involved in the binding of ivabradine.	Ivabradine	185-195	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	90-93	
34041946-6	2021	The profiles of these blockers were distinct from those of the previously reported HCN channel blockers ivabradine and ZD7288.	Ivabradine	104-114	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	83-86	
33737235-6	2021	Ivabradine is a selective heart rate reducing agent, an inhibitor of HCN channels, currently approved for the treatment of coronary artery disease and chronic heart failure.	Ivabradine	0-10	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	69-72	
34059279-6	2021	As a proof of concept, we describe here the protocol for monitoring the binding of the second messenger cAMP and of the known HCN drug Ivabradine to the purified GFP-HCN4 channel.	Ivabradine	135-145	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	126-129	
29806042-2	2018	Even newly released anti-arrhythmic drugs, like ivabradine with HCN channel as a primary target, block the hERG potassium current in overlapping concentration interval.	Ivabradine	48-58	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	64-67	
28821541-4	2017	METHODS AND RESULTS: As in rodents, the intrinsic heart rate was significantly lower in human athletes than in nonathletes, and in all subjects, the rate-lowering effect of the HCN selective blocker, ivabradine, was significantly correlated with the intrinsic heart rate, consistent with HCN repression in athletes.	Ivabradine	200-210	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	177-180	
28821541-4	2017	METHODS AND RESULTS: As in rodents, the intrinsic heart rate was significantly lower in human athletes than in nonathletes, and in all subjects, the rate-lowering effect of the HCN selective blocker, ivabradine, was significantly correlated with the intrinsic heart rate, consistent with HCN repression in athletes.	Ivabradine	200-210	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	288-291